104 related articles for article (PubMed ID: 12834858)
1. Tumor necrosis factor alpha promoter polymorphisms at position -308 in Taiwanese chronic hepatitis C patients treated with interferon-alpha.
Yu ML; Dai CY; Chiu CC; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chen CJ; Chuang WL; Chang WY
Antiviral Res; 2003 Jun; 59(1):35-40. PubMed ID: 12834858
[TBL] [Abstract][Full Text] [Related]
2. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C.
Dai CY; Chuang WL; Lee LP; Chen SC; Hou NJ; Lin ZY; Hsieh MY; Hsieh MY; Wang LY; Chang WY; Yu ML
J Viral Hepat; 2006 Nov; 13(11):770-4. PubMed ID: 17052277
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor- alpha promoter polymorphism at position -308 predicts response to combination therapy in hepatitis C virus infection.
Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Hsieh MY; Hou NJ; Lin ZY; Huang JF; Hsieh MY; Wang LY; Yu ML
J Infect Dis; 2006 Jan; 193(1):98-101. PubMed ID: 16323137
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C.
Rosen HR; McHutchison JG; Conrad AJ; Lentz JJ; Marousek G; Rose SL; Zaman A; Taylor K; Chou S
Am J Gastroenterol; 2002 Mar; 97(3):714-20. PubMed ID: 11922568
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
6. Response to combination therapy with interferon alfa-2a and ribavirin in chronic hepatitis C according to a TNF-alpha promoter polymorphism.
Schiemann U; Glas J; Török P; Simperl C; Martin K; König A; Schmidt F; Schaefer M; Folwaczny C
Digestion; 2003; 68(1):1-4. PubMed ID: 12949432
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
Zografos TA; Liaskos C; Rigopoulou EI; Togousidis E; Makaritsis K; Germenis A; Dalekos GN
Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
[TBL] [Abstract][Full Text] [Related]
8. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
[TBL] [Abstract][Full Text] [Related]
9. IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients.
Hsu CS; Hsu SJ; Liu WL; Chen CL; Liu CJ; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2013; 18(4):599-606. PubMed ID: 23296193
[TBL] [Abstract][Full Text] [Related]
10. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3.
Abbas Z; Moatter T; Hussainy A; Jafri W
World J Gastroenterol; 2005 Nov; 11(42):6656-61. PubMed ID: 16425360
[TBL] [Abstract][Full Text] [Related]
11. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection.
Wietzke-Braun P; Maouzi AB; Mänhardt LB; Bickeböller H; Ramadori G; Mihm S
Eur J Gastroenterol Hepatol; 2006 Sep; 18(9):991-7. PubMed ID: 16894313
[TBL] [Abstract][Full Text] [Related]
12. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C.
Dumoulin FL; Wennrich U; Nischalke HD; Leifeld L; Fischer HP; Sauerbruch T; Spengler U
J Hum Virol; 2001; 4(4):195-9. PubMed ID: 11694847
[TBL] [Abstract][Full Text] [Related]
13. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C.
Toyoda M; Kakizaki S; Horiguchi N; Sato K; Takayama H; Takagi H; Nagamine T; Mori M
Liver; 2000 Jul; 20(4):305-11. PubMed ID: 10959809
[TBL] [Abstract][Full Text] [Related]
14. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C.
Karino Y; Toyota J; Sugawara M; Miyazaki K; Kuwata Y; Yamazaki K; Sato T; Ohmura T; Matsushima T
J Gastroenterol Hepatol; 2003 Apr; 18(4):404-10. PubMed ID: 12653888
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of the association between chronic hepatitis B and C infections and TNF-α (-308) gene polymorphism].
Börekçi G; Aras N; Kandemir Ö; Yalın S; Karakaş Çelik S; Berköz M
Mikrobiyol Bul; 2016 Apr; 50(2):236-44. PubMed ID: 27175496
[TBL] [Abstract][Full Text] [Related]
17. Association of Myxovirus Resistance Gene Promoter Polymorphism with Response to Combined Interferon Treatment and Progression of Liver Disease in Chronic HCV Egyptian Patients.
Bader El Din NG; Salum GM; Anany MA; Ibrahim MK; Dawood RM; Zayed N; El Abd YS; El-Shenawy R; El Awady MK
J Interferon Cytokine Res; 2015 Aug; 35(8):641-8. PubMed ID: 25868067
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism of tumor necrosis factor-α and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-α therapy response.
Dogra G; Chakravarti A; Kar P; Chawla YK
Hum Immunol; 2011 Oct; 72(10):935-9. PubMed ID: 21756957
[TBL] [Abstract][Full Text] [Related]
19. Preliminary results of individual therapy of chronic hepatitis C by Ukrain and interferon-alpha.
Voltchek I; Sologub T; Nowicky JW; Grigoryeva T; Belozyorova L; Belopolskaya M; Semenyako N; Lamanova E
Drugs Exp Clin Res; 2000; 26(5-6):261-6. PubMed ID: 11345036
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection.
Höhler T; Kruger A; Gerken G; Schneider PM; Meyer zum Büschenfelde KH; Rittner C
J Med Virol; 1998 Mar; 54(3):173-7. PubMed ID: 9515764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
